Market Views – Page 22 – media

Pfizer lines up an $830M alliance with Arvinas on protein degradation

Pfizer has signed on to fund the launch of a hunt for a slate of small molecules that can degrade proteins, a key therapeutic pathway that’s been playing a role in prostate cancer and other areas.
- Source: Endpts
- 489
- January 10, 2018
C4 Therapeutics Market Views Pfizer protein degradation
Busy Takeda Takes Out Tigenix in $630M Deal

Shares of Belgium-based TiGenix NV shot up more than 72 percent in pre-market trading after Japan’s Takeda Pharmaceuticals opted to acquire the company with which it has a developmental partnership for $630 million.
- Source: Biospace
- 513
- January 9, 2018
Market Views pharmaceutical company stem cells
Sangamo and Pfizer announce collaboration for development of zinc finger protein gene therapy for ALS

Sangamo Therapeutics, Inc. and Pfizer Inc. announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
- Source: Prnewswire
- 447
- January 9, 2018
ALS FTLD Market Views neurodegenerative disease
Addex, Indivior Forge $335M Addiction Disorder Tie-Up

Indivior announced that Indivior UK Limited has entered into a strategic collaboration with Addex Pharma S.A., a wholly-owned subsidiary of Addex Therapeutics (SIX: ADXN) ("Addex"), in the field of GABAB positive allosteric modulators (PAMs). GABAB PAMs have demonstrated preclinical efficacy and tolerability in animal models for alcohol use disorder (AUD) and cocaine use disorder (CUD)1,2.
- Source: Biospace
- 419
- January 8, 2018
AUD CUD GABAB PAM Market Views
Pfizer, Novartis and more post price hikes

It's not just specialty drugmakers raising prices in recent days. Big Pharma has pushed through a spate of increases, and while all of them are sub-10%—the cap some companies have adopted—some of them will cost payers and consumers plenty.
- Source: fiercepharma
- 466
- January 5, 2018
drugmaker Market Views price increase
The Quantified Self, Our Wearable Future

Smaller, smarter, more efficient and prettier…. Wearables are becoming increasingly more popular. Where first only sport fanatics and early tech adopters were interested, we now see that the high tech wearable devices become more common and accepted.
- Source: Digital Salutem
- 1,219
- January 5, 2018
healthcare technology Market Views medical device mHealth wearables
How to Keep Health Data Safe in the Age of Disruptive Technologies

The health system has developed AI-based algorithms used on its more than 27 petabytes of data to define patient subpopulations — those with congestive heart failure or asthma, for instance — to target interventions to those groups. It’s developed algorithms using electronic health record data to predict patient decline in hospitals.
- Source: HealthTech Magazine
- 557
- January 4, 2018
AI blockchain disruptive technology healthcare technology Market Views
The Healthcare Technology Winners of 2017

It’s been a big year in healthcare technology. Healthcare Analytics News™ reached out to experts across our 8 coverage areas to determine which companies, people, and projects made the biggest waves. The winners of 2017 ushered in advances that have turned heads, resulted in measurable improvements, and given reason to believe that this high-speed sector is not built on hype alone.
- Source: hcanews
- 489
- January 1, 2018
healthcare technology Market Views
Top 5 Digital Health Trends——A Look Back At 2017

Digital health made big strides in 2017. With better provider workflows and more integrated core healthcare platforms, healthcare is on the brink of a disruption. As we move into 2018 and the next wave of innovation, here is a look back on the biggest stories that moved the needle in digital health this year.
- Source: forbes
- 790
- January 1, 2018
digital health Market Views
Mallinckrodt inks $1.2B Sucampo buy, ending rough 2017 on a high note

Mallinckrodt, which has landed in hot water multiple times this year, is diversifying beyond its controversial lead seller.
- Source: fiercepharma
- 438
- December 28, 2017
chronic Company Insight constipation Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.